Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Opportunities to Optimize Cancer Policies Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mar

Today In Oncology

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Opportunities to Optimize Cancer Policies Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Can Viral Respiratory Infections Increase Lung Cancer Risk

Female Reproductive Cancers Linked to Reduced Survival Advantage Over Males

Early Study Evaluates Two-Vaccine Strategy in T-Cell Lymphoma

Structured Exercise Plan for Patients With Cancer May Reduce Cognitive Effects of Chemotherapy

Risk of Breast Cancer After Ovarian Cancer in Women With BRCA1/2 Variants